Ardelyx (ARDX) Competitors

$6.61
+0.21 (+3.28%)
(As of 05/1/2024 ET)

ARDX vs. ZLAB, DVAX, PTGX, AVDL, TARO, AKRO, MORF, EWTX, SUPN, and KURA

Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Zai Lab (ZLAB), Dynavax Technologies (DVAX), Protagonist Therapeutics (PTGX), Avadel Pharmaceuticals (AVDL), Taro Pharmaceutical Industries (TARO), Akero Therapeutics (AKRO), Morphic (MORF), Edgewise Therapeutics (EWTX), Supernus Pharmaceuticals (SUPN), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical preparations" industry.

Ardelyx vs.

Zai Lab (NASDAQ:ZLAB) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.

Ardelyx received 297 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 67.58% of users gave Ardelyx an outperform vote while only 63.58% of users gave Zai Lab an outperform vote.

CompanyUnderperformOutperform
Zai LabOutperform Votes
220
63.58%
Underperform Votes
126
36.42%
ArdelyxOutperform Votes
517
67.58%
Underperform Votes
248
32.42%

Zai Lab has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.

Zai Lab currently has a consensus target price of $64.22, indicating a potential upside of 305.19%. Ardelyx has a consensus target price of $12.69, indicating a potential upside of 93.70%. Given Ardelyx's higher probable upside, equities research analysts clearly believe Zai Lab is more favorable than Ardelyx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ardelyx
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 5.2% of Zai Lab shares are held by insiders. Comparatively, 5.5% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Zai Lab had 4 more articles in the media than Ardelyx. MarketBeat recorded 9 mentions for Zai Lab and 5 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.09 beat Zai Lab's score of 0.49 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ardelyx has lower revenue, but higher earnings than Zai Lab. Ardelyx is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$266.72M5.96-$334.62M-$3.45-4.64
Ardelyx$124.46M12.26-$66.07M-$0.30-21.87

Ardelyx has a net margin of -53.08% compared to Ardelyx's net margin of -125.46%. Ardelyx's return on equity of -37.07% beat Zai Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-125.46% -37.07% -30.72%
Ardelyx -53.08%-43.57%-26.03%

Summary

Ardelyx beats Zai Lab on 12 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.53B$6.62B$4.88B$7.44B
Dividend YieldN/A2.90%2.81%3.95%
P/E Ratio-21.8711.76193.5515.99
Price / Sales12.26293.922,465.5185.40
Price / CashN/A30.5846.4935.50
Price / Book9.115.884.734.25
Net Income-$66.07M$140.75M$102.52M$213.95M
7 Day Performance2.02%1.80%1.33%0.09%
1 Month Performance-11.47%-9.87%-6.01%-5.38%
1 Year Performance41.08%-2.15%4.45%5.93%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZLAB
Zai Lab
2.4016 of 5 stars
$14.99
+6.5%
$64.22
+328.4%
-54.8%$1.49B$266.72M-4.342,175Upcoming Earnings
Positive News
DVAX
Dynavax Technologies
4.1659 of 5 stars
$11.84
+0.3%
$25.00
+111.1%
+9.2%$1.55B$232.28M-197.30408Upcoming Earnings
News Coverage
PTGX
Protagonist Therapeutics
1.2518 of 5 stars
$26.61
+3.9%
$36.00
+35.3%
+11.1%$1.55B$60M-17.86112Upcoming Earnings
AVDL
Avadel Pharmaceuticals
2.0079 of 5 stars
$17.30
-0.2%
$22.57
+30.5%
+73.3%$1.57B$27.96M-8.48154Upcoming Earnings
News Coverage
TARO
Taro Pharmaceutical Industries
0.911 of 5 stars
$42.28
+0.1%
$43.00
+1.7%
+68.7%$1.59B$572.95M34.661,554
AKRO
Akero Therapeutics
3.1908 of 5 stars
$20.79
+0.1%
$37.71
+81.4%
-55.5%$1.44BN/A-7.2955News Coverage
MORF
Morphic
3.7268 of 5 stars
$28.50
+1.8%
$61.00
+114.0%
-42.3%$1.43B$520,000.00-8.17121
EWTX
Edgewise Therapeutics
1.6302 of 5 stars
$15.08
-1.0%
$31.20
+106.9%
+104.6%$1.40BN/A-9.5488Gap Up
SUPN
Supernus Pharmaceuticals
3.9327 of 5 stars
$29.71
+1.1%
$41.00
+38.0%
-18.3%$1.63B$607.52M0.00652Upcoming Earnings
News Coverage
KURA
Kura Oncology
3.3056 of 5 stars
$18.19
+3.8%
$28.28
+55.5%
+101.4%$1.39BN/A-8.75142Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:ARDX) was last updated on 5/1/2024 by MarketBeat.com Staff

From Our Partners